4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses
about
CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligandModulation of T-cell responses to alloantigens by TR6/DcR3Signaling in Effector Lymphocytes: Insights toward Safer ImmunotherapyNatural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer ImmunotherapyMelanoma: oncogenic drivers and the immune system4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaquesEngineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses4-1BB agonism: adding the accelerator to cancer immunotherapy4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicityHuman 4-1BB regulates CD28 co-stimulation to promote Th1 cell responsesGalectin-9 controls the therapeutic activity of 4-1BB-targeting antibodiesCombination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine productionCancer immunotherapy via dendritic cellsCD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine.Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions.The oxazolidinone derivative locostatin induces cytokine appeasement.Antibody Therapies in Cancer.Molecular cloning of agonistic and antagonistic monoclonal antibodies against human 4-1BB.Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated miceTherapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies.Expression of 4-1BB and 4-1BBL in thymocytes during thymus regenerationA novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice.Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity.Expression and Function of TLR2 on CD4 Versus CD8 T Cells.Targeting peripheral blood pro-inflammatory cytotoxic lymphocytes by inhibiting CD137 expression: novel potential treatment for COPDDifferential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells.Role of CD28/CD80-86 and CD40/CD154 costimulatory interactions in host defense to primary herpes simplex virus infection.Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model.Role of 4-1BB receptor in the control played by CD8(+) T cells on IFN-gamma production by Mycobacterium tuberculosis antigen-specific CD4(+) T CellsAsialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection.Metabolic reprogramming towards aerobic glycolysis correlates with greater proliferative ability and resistance to metabolic inhibition in CD8 versus CD4 T cells.CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)Review article: molecular signals and genetic reprogramming in peripheral T-cell differentiation.Antibody-based immunotherapy for malignant glioma.4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
P2860
Q24647213-B456BDC0-45D5-4A4A-B415-D069AB351EA8Q24672018-8EEEFFA0-3FDA-44DF-A561-50784E4F6945Q26744654-FF95DCA0-5896-4371-A3F6-B28547271D9BQ26772347-00366D42-C81D-4C6A-A439-0484430F8501Q26775598-647EC115-0D76-4DD3-8A88-3D2C4BAFD559Q27012963-8EA6BF78-5A48-4C47-A691-EE6D89C797B9Q27314155-93CD5232-0314-436B-A344-724F77EFF1F6Q27678516-0CAE7153-CA8E-443E-9E9C-B53C0327F38EQ28072933-2DC55436-BFC8-4944-930D-0B8E50663595Q28079622-477F02AB-B7EA-4842-84D2-01C55883AACCQ28217502-D8A7DDC6-ED30-4048-B4AF-BEC25FFFAE4BQ28267489-C491D837-D381-4E24-8849-1CD1481903FCQ28656460-5346B356-7C0C-4157-A367-3786D37E80DDQ28740530-D5F965A4-A455-4543-AD38-BC9CAEA4493DQ29615444-D477C853-831A-4B01-BCE4-63A00E74C687Q30573747-150955D8-1E05-498E-96F1-F86E26903E03Q30830664-C330F581-A41E-455A-9B46-E20248C97767Q30873726-691FE349-550C-4711-A4AA-32A0B50084F8Q30887007-3B230BF2-EA61-4D0B-82B7-A69AF9F4EF1DQ31104000-EB7CE5B5-C34E-4E59-8ABC-D5DBCDE27DC6Q33184750-D560E296-16E7-43B6-B5A2-39CDA4F9031FQ33374623-5517020D-99E8-4D63-BE0A-A03E0CE59B29Q33426409-724E9F99-4CEE-4B3F-9895-A53D627ED24CQ33575781-A21BEF71-9C03-405F-8FFD-5BB0E42A3853Q33586493-69303535-664E-4C0E-9A2C-9703A6CE70B8Q33603041-10385918-1DE9-4229-BA83-E3B9374EA322Q33624219-05FFB06E-1425-42C1-AE30-FCFD5209D2E5Q33631927-B147999B-B9D6-45A1-BF5E-E04BBD0537ACQ33760782-A459C843-CFED-48DE-81A7-9BC235E76AECQ33768093-EFD89E44-91E4-452B-A3C5-D01AA534F10AQ33835246-889B37FA-1C33-4F6B-9CEB-FDFAE79CE64FQ33889603-87ADFCC0-387B-4D0C-9516-6E3979034D34Q33900380-FD8BB932-A791-49A6-BAD8-EA3C6F142082Q33903407-DFAE6C03-2111-4925-8E3E-F9C4225EAF40Q34000160-83FD2CF4-20C1-4842-8FA2-30846EA6C5EAQ34025520-56AF1292-89BD-4C9C-ADBD-93012FDD0EE6Q34073529-96C27710-8AAA-4B28-92FE-A7900EC326AAQ34099106-B2B075D3-A1DF-4A14-8E55-8D52B090B04DQ34120472-89311491-A8F0-40D3-B859-368D3AC2E8ACQ34180031-04DF5504-2504-4E38-A2D8-0248FAB758EE
P2860
4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
4-1BB costimulatory signals pr ...... of cytotoxic T cell responses
@ast
4-1BB costimulatory signals pr ...... of cytotoxic T cell responses
@en
type
label
4-1BB costimulatory signals pr ...... of cytotoxic T cell responses
@ast
4-1BB costimulatory signals pr ...... of cytotoxic T cell responses
@en
prefLabel
4-1BB costimulatory signals pr ...... of cytotoxic T cell responses
@ast
4-1BB costimulatory signals pr ...... of cytotoxic T cell responses
@en
P2093
P2860
P356
P1476
4-1BB costimulatory signals pr ...... of cytotoxic T cell responses
@en
P2093
Chalupny J
Emswiler J
Klussman K
Ledbetter JA
Mittler RS
Pearson TC
P2860
P356
10.1084/JEM.186.1.47
P407
P577
1997-07-01T00:00:00Z